12/4
07:18 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
12/3
08:44 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
11/18
01:20 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/15
01:42 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
11/12
01:30 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
09:06 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its price target raised by analysts at Citizens Jmp from $254.00 to $259.00. They now have a "market outperform" rating on the stock.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its price target raised by analysts at Citizens Jmp from $254.00 to $259.00. They now have a "market outperform" rating on the stock.
11/11
08:44 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was given a new $259.00 price target on by analysts at JMP Securities.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was given a new $259.00 price target on by analysts at JMP Securities.
11/11
07:03 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
11/10
04:32 pm
sprb
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Low
Report
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
11/10
04:05 pm
sprb
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Low
Report
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/7
01:15 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
08:09 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $254.00 price target on the stock.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $254.00 price target on the stock.
10/28
07:03 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Citigroup Inc. to an "outperform" rating.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Citigroup Inc. to an "outperform" rating.
10/28
06:01 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was given a new $254.00 price target on by analysts at JMP Securities.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was given a new $254.00 price target on by analysts at JMP Securities.
10/25
07:12 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
High
Report
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/21
03:58 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) was given a new $160.00 price target on by analysts at Leerink Partners.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was given a new $160.00 price target on by analysts at Leerink Partners.
10/18
07:32 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/14
12:16 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
08:28 am
sprb
Spruce Biosciences Announces $50.0 Million Private Placement Financing [Yahoo! Finance]
Medium
Report
Spruce Biosciences Announces $50.0 Million Private Placement Financing [Yahoo! Finance]
10/8
08:00 am
sprb
Spruce Biosciences Announces $50.0 Million Private Placement Financing
Medium
Report
Spruce Biosciences Announces $50.0 Million Private Placement Financing
10/7
10:39 am
sprb
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) [Seeking Alpha]
High
Report
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) [Seeking Alpha]
10/6
03:24 pm
sprb
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy [Seeking Alpha]
Medium
Report
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy [Seeking Alpha]
10/6
08:45 am
sprb
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) [Yahoo! Finance]
High
Report
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) [Yahoo! Finance]
10/6
08:00 am
sprb
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
High
Report
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
9/15
07:00 am
sprb
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
High
Report
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market